| Jose Carlos Garcia Blanco, MD | |
|
2250 Latham St Apt 34, Mountain View, CA 94040-1644 | |
| (106) 029-1202 | |
| Not Available |
| Full Name | Jose Carlos Garcia Blanco |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 12 Years |
| Location | 2250 Latham St Apt 34, Mountain View, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184001976 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional Medical Center Of San Jose | San jose, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inpatient Specialists Of California Pc | 3476864448 | 289 |
News Archive
A selection of health policy stories from Michigan, Tennessee, California, Wisconsin, New York and North Carolina.
The Research Group headed by molecular biologist Andrea Pichler from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has made an important discovery in meiosis research.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Cancerous tumors must be fed. Their unregulated growth requires a steady stream of blood flow and nutrients. Thus, one way that researchers have tried to wipe out cancer is to target cells undergoing the metabolic shifts that enable a tumor's rapid growth.
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.
› Verified 7 days ago
| Entity Name | Inpatient Specialists Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952792475 PECOS PAC ID: 3476864448 Enrollment ID: O20150617000915 |
News Archive
A selection of health policy stories from Michigan, Tennessee, California, Wisconsin, New York and North Carolina.
The Research Group headed by molecular biologist Andrea Pichler from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has made an important discovery in meiosis research.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Cancerous tumors must be fed. Their unregulated growth requires a steady stream of blood flow and nutrients. Thus, one way that researchers have tried to wipe out cancer is to target cells undergoing the metabolic shifts that enable a tumor's rapid growth.
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jose Carlos Garcia Blanco, MD 1475 Nw 12th Ave, Miami, FL 33136-1002 Ph: (305) 243-6387 | Jose Carlos Garcia Blanco, MD 2250 Latham St Apt 34, Mountain View, CA 94040-1644 Ph: (106) 029-1202 |
News Archive
A selection of health policy stories from Michigan, Tennessee, California, Wisconsin, New York and North Carolina.
The Research Group headed by molecular biologist Andrea Pichler from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has made an important discovery in meiosis research.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Cancerous tumors must be fed. Their unregulated growth requires a steady stream of blood flow and nutrients. Thus, one way that researchers have tried to wipe out cancer is to target cells undergoing the metabolic shifts that enable a tumor's rapid growth.
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.
› Verified 7 days ago
Sevwandi De Silva, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7144 | |
Dr. Gayathri Thiru, M.D Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2490 Hospital Drive, Suite 212, Mountain View, CA 94040 Phone: 408-900-8077 Fax: 844-965-9436 | |
Dr. Shawn Mathew Jacob, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2500 Grant Rd, Mountain View, CA 94040 Phone: 650-940-7000 | |
Dr. Vibha Ramaswamy Iyengar, M.D, MPH Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7808 | |
Geoffrey Yoon, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-404-8300 | |
Dr. David Alan Reinert, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7000 | |
Apurva Marfatia, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Medical Staff, Mountain View, CA 94040 Phone: 650-934-7144 |